Quick Answer
Nuvectis Pharma, Inc. reported Net Income of -$26.44 million for fiscal year 2025.
Nuvectis Pharma, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$26.44M | -39.2% |
| 2024 | -$19.00M | +14.6% |
| 2023 | -$22.26M | -16.6% |
| 2022 | -$19.09M | -48.1% |
| 2021 | -$12.89M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$7.46M | -79.7% | -17.8% |
| June 30, 2025 | -$6.33M | -43.0% | -18.8% |
| March 31, 2025 | -$5.33M | -27.8% | -28.4% |
| September 30, 2024 | -$4.15M | +29.4% | +6.2% |
| June 30, 2024 | -$4.43M | +22.4% | -6.2% |
| March 31, 2024 | -$4.17M | -3.0% | +29.1% |
| September 30, 2023 | -$5.88M | -0.1% | -3.0% |
| June 30, 2023 | -$5.71M | -59.9% | -41.0% |
- Nuvectis Pharma, Inc. showed a decrease of -39.2% in Net Income compared to the prior fiscal year.
- Over the 2021–2025 period, Nuvectis Pharma, Inc.’s net income has declined by 105.1% (from -$12.89 million to -$26.44 million).
- The most recent figure is from Nuvectis Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: